Related references
Note: Only part of the references are listed.
Article
Virology
Mahmoud Kandeel et al.
Summary: The study investigates the evolutionary relationships and similarities between the Omicron variant and other SARS-CoV-2 variants, finding that the Omicron variant forms a new monophyletic clade distant from other variants.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Virology
Lulan Wang et al.
Summary: The discovery of the Omicron variant has sparked global concerns about its mutations, transmission, and immune escape properties. Current research suggests that the variant may impact viral infectivity and host immunity, and it may evolve from clade 20B.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Review
Immunology
Makoto Takeda
Summary: This review discusses the crucial role of S protein cleavage in coronavirus infection, particularly focusing on SARS-CoV-2. The complexity of the cleavage activation mechanism of the S protein is highlighted, with different cleavage sites and motifs involved. Variants of concern with enhanced infectivity have emerged during the ongoing pandemic, demonstrating the significant impact of changes in S protein cleavability on viral infectivity and virulence.
MICROBIOLOGY AND IMMUNOLOGY
(2022)
Article
Immunology
Youchun Wang et al.
Summary: The Omicron variant shows greater potential for immune escape compared to other variants, suggesting a significant impact on immunity from previous infections and vaccines.
EMERGING MICROBES & INFECTIONS
(2022)
Article
Multidisciplinary Sciences
Yaara Finkel et al.
Summary: A high-resolution map of coding regions in the SARS-CoV-2 genome enables the identification of 23 unannotated open reading frames and quantification of the expression of canonical viral open reading frames.
Article
Multidisciplinary Sciences
Jessica A. Plante et al.
Summary: The D614G substitution in the SARS-CoV-2 spike protein enhances viral replication and infectivity in human lung epithelial cells, primary airway tissues, and hamsters. This variant may increase transmission in the upper respiratory tract and doesn't seem to significantly reduce vaccine efficacy. Further research on therapeutic antibodies targeting the circulating G614 virus is recommended.
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran et al.
Summary: Severe cases of COVID-19 show increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high antibody levels. High neutralization potency is a predictor of survival. Patient sera can neutralize different strains, indicating cross-protection from reinfection.
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.
Article
Multidisciplinary Sciences
Thomas G. Flower et al.
Summary: The crystal structure of SARS-CoV-2 ORF8 was determined at 2.04-angstrom resolution by X-ray crystallography, revealing unique dimerization interfaces that may allow the protein to form large-scale assemblies, potentially mediating immune suppression and evasion activities.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Cell Biology
Sophie M-C Gobeil et al.
Summary: The study found that the mutation variant G614 of SARS-CoV-2 leads to significant changes in the protein structure, resulting in altered positioning ratio of RBD, which may have implications for vaccine design.
Article
Biochemistry & Molecular Biology
Qianqian Li et al.
Summary: The 501Y.V2 variants of SARS-CoV-2 with multiple mutations are rapidly spreading from South Africa to other countries, showing reduced susceptibility to neutralizing antibodies and potential compromise of monoclonal antibodies and vaccines. Enhanced infectivity in murine ACE2-overexpressing cells suggests the possibility of transmission to mice.
Article
Biochemistry & Molecular Biology
Piyada Supasa et al.
Summary: Research on the UK-dominant variant B.1.1.7 shows that it is harder to neutralize than the parental virus, but widespread escape from antibodies or monoclonal antibodies has not been observed yet.
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran et al.
Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.
Article
Biochemistry & Molecular Biology
Daming Zhou et al.
Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.
Article
Microbiology
Xiaoying Shen et al.
Summary: Current COVID-19 vaccines target the ancestral SARS-CoV-2 spike, but the emerging B.1.1.7 variant with multiple spike mutations may impact some antibody therapies while posing no major concerns for vaccine efficacy or increased risk of reinfection.
CELL HOST & MICROBE
(2021)
Article
Microbiology
Jing-wen Lin et al.
Summary: This study utilized an integrative approach to analyze mutations of the SARS-CoV-2 virus, identifying 35 recurrent variants of clinical importance, with one variant associated with severe clinical phenotypes. The findings suggest that mutations in Nsp1 may have implications for molecular diagnostics and drug design.
CELL HOST & MICROBE
(2021)
Article
Microbiology
Zhuoming Liu et al.
Summary: The study found that antibodies targeting the SARS-CoV-2 spike protein have escape mutations, different monoclonal antibodies have unique resistance profiles, some mutants are resistant to multiple antibodies while some variants can escape neutralization by convalescent sera. Comparing antibody-mediated mutations with circulating SARS-CoV-2 sequences revealed substitutions that may weaken neutralizing immune responses in some individuals, warranting further investigation.
CELL HOST & MICROBE
(2021)
Review
Microbiology
Jessica A. Plante et al.
Summary: Despite the development of vaccines, COVID-19 caused by SARS-CoV-2 continues to be a global concern due to the emergence of new variants, raising worries about increased spread and potential impacts on immunity.
CELL HOST & MICROBE
(2021)
Article
Evolutionary Biology
Zhenglin Zhu et al.
Summary: The study reports nine newly evolved SARS-CoV-2 single nucleotide polymorphism (SNP) alleles that underwent rapid changes in frequency within the initial four months. These mutations show potential effects on virus replication and disease severity in COVID-19 patients, providing important insights for future epidemiological surveys and disease control.
GENOME BIOLOGY AND EVOLUTION
(2021)
News Item
Multidisciplinary Sciences
Ewen Callaway
Article
Biochemistry & Molecular Biology
Patrick Tang et al.
Summary: mRNA COVID-19 vaccines demonstrate high effectiveness in preventing severe outcomes and death caused by the Delta variant in Qatar, despite lower effectiveness at blocking infection.
Editorial Material
Medicine, General & Internal
John P. Moore et al.
Summary: This article reviews the circulating SARS-CoV-2 genetic variants and the mechanisms of immunity by which they may escape vaccine-induced protection, proposing 6 measures to address these issues, including enhanced variant isolation and testing procedures, and continued adherence to mask-wearing and other established public health measures.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Denis Y. Logunov et al.
Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.
Editorial Material
Medicine, General & Internal
Arnaud Fontanet et al.
Editorial Material
Medicine, General & Internal
Ester C. Sabino et al.
News Item
Multidisciplinary Sciences
Ewen Callaway et al.
Article
Multidisciplinary Sciences
Dami A. Collier et al.
Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.
News Item
Multidisciplinary Sciences
Ewen Callaway et al.
Article
Biochemistry & Molecular Biology
Rita E. Chen et al.
Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.
Article
Biochemistry & Molecular Biology
Constantinos Kurt Wibmer et al.
Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.
Letter
Medicine, General & Internal
Kai Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Editorial Material
Multidisciplinary Sciences
Daniel M. Altmann et al.
Article
Multidisciplinary Sciences
Alexander Muik et al.
Summary: A new SARS-CoV-2 lineage B.1.1.7 has emerged in the UK, which is more transmissible and faster spreading than other strains. However, a study found that the BNT162b2 vaccine offers largely preserved protection against the B.1.1.7 lineage, despite some reduced neutralizing titers.
Article
Multidisciplinary Sciences
Seiya Ozono et al.
Summary: The naturally occurring mutations of SARS-CoV-2 spike protein can affect cell entry, with the D614G mutation resulting in increased cell entry and maintaining susceptibility to neutralization by antisera against prototypic viruses. Further global surveillance is needed to understand the transmissibility of SARS-CoV-2 among humans.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Thanh Thi Nguyen et al.
Summary: This study analyzed genomic mutations in the coding regions of SARS-CoV-2 and their impact on protein secondary structure and solvent accessibility, indicating the establishment of a mutation dataset beneficial for virus tracking, as well as identifying stable coding genes suitable for vaccine and drug development.
SCIENTIFIC REPORTS
(2021)
Editorial Material
Medicine, General & Internal
Luke Taylor
BMJ-BRITISH MEDICAL JOURNAL
(2021)
News Item
Medicine, General & Internal
Ingrid Torjesen
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Biochemistry & Molecular Biology
Filipe Pereira
Summary: The SARS-CoV-2 Variant of Concern 202012/01 (VOC-202012/01) is a highly transmissible variant with a potential immune evasion ability due to truncation of the ORF8 gene. Although ORF8-deficient lineages are rare, they have been identified in relevant contexts and should be monitored closely.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Markus Hoffmann et al.
Summary: The emerging SARS-CoV-2 variants may exhibit resistance to existing neutralizing antibodies and treatments, which could have significant implications for pandemic containment efforts.
Article
Biochemistry & Molecular Biology
Wanwisa Dejnirattisai et al.
Summary: Ending the SARS-CoV-2 pandemic requires global vaccination. New virus strains with mutations impact antibody responses, but some variants are less resistant than others. A monoclonal antibody can neutralize different variants and partially restore neutralization potency for other public antibodies.
Article
Microbiology
Alona Kuzmina et al.
Summary: Vaccines that induce high levels of neutralizing antibodies are crucial in combating COVID-19, but some variants of SARS-CoV-2 show resistance to neutralization, raising concerns about vaccine efficacy.
CELL HOST & MICROBE
(2021)
Article
Microbiology
Venkata Viswanadh Edara et al.
Summary: Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant.
CELL HOST & MICROBE
(2021)
Article
Infectious Diseases
Therese Staub et al.
Summary: Four cases of SARS-CoV-2 re-infections with a B.1.351 variant in 2021 were reported among healthcare workers in a hospital near the border between France and Luxembourg. The healthcare workers initially used surgical masks as recommended, but switched to FFP2 masks after a cluster outbreak of the B.1.351 variant.
Article
Medicine, General & Internal
Katherine R. W. Emary et al.
Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.
Article
Multidisciplinary Sciences
Nicholas G. Davies et al.
Summary: Studies have shown that the SARS-CoV-2 B.1.1.7 lineage is more transmissible and may cause more severe illness compared to pre-existing variants.
Article
Multidisciplinary Sciences
Erik Volz et al.
Summary: Genetic and testing data from England indicate that the SARS-CoV-2 variant B.1.1.7 has a transmission advantage over other lineages, showing a rapid expansion during autumn 2020. Analysis of S gene target failures (SGTF) in community-based diagnostic PCR testing suggests that B.1.1.7 is more transmissible than non-variant of concern lineages and has a significant transmission advantage, with a reproduction number 50% to 100% higher. Additionally, cases of B.1.1.7 appear to include a larger share of under 20-year-olds compared to non-variant cases.
Letter
Medicine, General & Internal
Laith J. Abu-Raddad et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Guo-Lin Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. A. Madhi et al.
Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
V. Shinde et al.
Summary: The NVX-CoV2373 vaccine showed efficacy in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Virology
Daniele Focosi et al.
Summary: The Spike protein serves as the target for antibody-based therapeutics and vaccines, but mutations in Spike could impact their efficacy. Monitoring mutations is crucial for adjusting the therapeutics inventory. Different clades exhibit varying mutation combinations, with a focus on the UK, South African, and Brazilian variants.
REVIEWS IN MEDICAL VIROLOGY
(2021)
Article
Virology
Ronaldo da Silva Francisco Jr et al.
Summary: The emergence of novel SARS-CoV-2 lineages, including B.1.1.28 (E484K), in Rio Grande do Sul, Brazil has raised global concerns. Co-infection events and the identification of a new sample cluster named VUI-NP13L underscore the importance of strict and effective social distancing measures to combat the spread of potentially more hazardous SARS-CoV-2 strains.
Article
Biology
Jun Chen et al.
Summary: Despite strict control measures, the COVID-19 pandemic continues to rage globally. Scientists are encouraging herd immunity, highlighting the precarious nature of immunity generated after natural infection. Vaccines are considered the most promising approach to return to normality, but concerns remain regarding their accessibility, vaccination rate, and efficacy against emerging virus variants.
Article
Public, Environmental & Occupational Health
Mark S. Graham et al.
Summary: The study showed that the B.1.1.7 variant did not result in changes in COVID-19 symptoms or duration of illness, and there was no significant increase in reinfection rate compared to previous variants.
LANCET PUBLIC HEALTH
(2021)
Article
Biochemistry & Molecular Biology
Chang Liu et al.
Summary: Recent study examined the neutralizing ability of monoclonal antibodies, convalescent and vaccine sera against the Indian variants B.1.617.1 and B.1.617.2, showing that the neutralization of these variants is reduced compared to the ancestral strains, without widespread antibody escape as seen in other variants like B.1.351.
Article
Infectious Diseases
Yaniv Lustig et al.
Summary: The study found that healthcare workers vaccinated with Comirnaty showed reduced neutralising titres against the Gamma, Beta, and Delta variants, but the remaining neutralisation capacity may still be protective.
Editorial Material
Public, Environmental & Occupational Health
Ying Liu et al.
Summary: The Delta variant is rapidly replacing other strains of SARS-CoV-2, with a higher R-0 value of 5.08 compared to the ancestral strain's 2.79. Increasing vaccine coverage and strengthening public health measures are now more urgent than ever to control the spread of the virus.
JOURNAL OF TRAVEL MEDICINE
(2021)
Article
Virology
Angela Choi et al.
Summary: The study demonstrates that vaccination with the mRNA-1273 COVID-19 vaccine produces neutralizing antibodies against various emerging variants, including variants of concern and interest. While neutralization of some variants may be reduced compared to the wild-type virus, the protective effect is still present, informing vaccination strategies against COVID-19.
JOURNAL OF VIROLOGY
(2021)
Letter
Medicine, General & Internal
Emma C. Wall et al.
Article
Medicine, General & Internal
Mine Durusu Tanriover et al.
Summary: The study presented the interim efficacy and safety results of the CoronaVac vaccine in a phase 3 clinical trial in Turkey, demonstrating high efficacy against PCR-confirmed symptomatic COVID-19 with good safety and tolerability profile. Results showed significant differences in the frequency of any adverse events between the vaccine and placebo groups, indicating excellent protective effects of the vaccine.
Letter
Infectious Diseases
Yuxin Chen et al.
LANCET INFECTIOUS DISEASES
(2021)
News Item
Multidisciplinary Sciences
David Adam
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.
Article
Multidisciplinary Sciences
Galit Alter et al.
Summary: The Ad26.COV2.S vaccine has shown clinical efficacy against symptomatic COVID-19, including the B.1.351 variant, but there is uncertainty regarding its immunogenicity against SARS-CoV-2 variants. The study found that neutralizing antibody responses were reduced against the B.1.351 and P.1 variants, while non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants.
Article
Multidisciplinary Sciences
Jianying Liu et al.
Summary: Serum samples from individuals vaccinated with the BNT162b2 vaccine can neutralize various SARS-CoV-2 variants, indicating mass immunization as a central strategy to end the global COVID-19 pandemic.
Review
Microbiology
William T. Harvey et al.
Summary: The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.
NATURE REVIEWS MICROBIOLOGY
(2021)
Article
Medicine, General & Internal
Alejandro Jara et al.
Summary: A study in Chile involving 10.2 million participants assessed the effectiveness of an inactivated SARS-CoV-2 vaccine developed in China. Fully immunized individuals had vaccine effectiveness of 65.9% for preventing Covid-19 and 87.5% for preventing hospitalization, 90.3% for preventing ICU admission, and 86.3% for preventing death.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Venkata-Viswanadh Edara et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Virology
Ahmed S. Abdel-Moneim et al.
Summary: SARS-CoV-2, a novel coronavirus, has caused over 100 million laboratory-confirmed cases worldwide. The virus is similar to a coronavirus from horseshoe bats and likely originated from spillover from bats or other wild animals to humans. Current data indicate that reinfection with SARS-CoV-2 is related to neutralizing antibodies levels, and there are sustained memory responses following infection. Vaccines and antivirals like remdesivir are being used to combat the virus, but evaluation against emerging variants is necessary.
Article
Immunology
Daryl Geers et al.
Summary: This study suggests that some variants might partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, but the S-specific CD4(+) T-cell activation is not affected by the mutations in the B.1.1.7 and B.1.351 variants.
SCIENCE IMMUNOLOGY
(2021)
Article
Immunology
Vladimir A. Gushchin et al.
Summary: Since the beginning of 2021, all the main six vaccines against COVID-19 have been used in mass vaccination globally. Concerns have been raised regarding the decreasing virus neutralization and epidemiological efficacy against certain genotypes, and further studies are needed to determine the effectiveness of the Sputnik V vaccine against variants of concern.
Article
Microbiology
Sarah Cherian et al.
Summary: Genomic epidemiology and whole genome sequencing were used to investigate the transmission and evolution of the SARS-CoV-2 virus during the global pandemic. The study identified new variants B.1.617.1 and B.1.617.2 in India, responsible for the second wave of COVID-19 in Maharashtra, with B.1.617.2 designated as a VOC delta and B.1.617.1 as a variant of interest kappa. Monitoring of these and emerging variants in India is crucial for public health.
Article
Multidisciplinary Sciences
Petra Mlcochova et al.
Summary: The B.1.617.2 (Delta) variant of SARS-CoV-2 has lower sensitivity to antibodies and higher replication efficiency compared to other lineages, which may contribute to its dominance and reduced vaccine effectiveness, highlighting the need for continued infection control measures post-vaccination.
Letter
Infectious Diseases
L. Kirola
Summary: Global proactive steps are being taken to fight against the SARS-CoV-2 pandemic and prevent COVID-19 spread, but the recent identification of the novel variant B.1.617.2 in India is rapidly transmitting to other countries, posing challenges to current therapeutics, widespread vaccination, and future research on COVID-19.
NEW MICROBES AND NEW INFECTIONS
(2021)
Review
Critical Care Medicine
Jasmin Khateeb et al.
Summary: Mutations in VOCs can increase the transmissibility of the virus and potentially impact vaccine efficacy, highlighting the need for combination therapeutic strategies.
Article
Biochemistry & Molecular Biology
Danielle C. Groves et al.
Summary: The global spread of the SARS-CoV-2 pandemic has triggered extensive genetic sequencing efforts to characterize the geographical distribution and molecular evolution of the virus. The emergence of the D614G variant as the dominant form worldwide has led to discussions about its effects on virus characteristics, clinical outcomes of infection, and host immune response.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Bas B. Oude Munnink et al.
Summary: Animal experiments have shown that various animals can be infected by SARS-CoV-2, with evidence of animal-to-human transmission within mink farms. Investigation into mink farm outbreaks revealed that the virus was initially introduced by humans and has since evolved, causing transmission between mink farms. Despite enhanced biosecurity measures and culling, transmission occurred between farms in three large clusters with unknown modes of transmission, resulting in a high percentage of infections among mink farm residents and employees.
Article
Medicine, General & Internal
Na Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Biochemistry & Molecular Biology
Dongwan Kim et al.
Article
Biochemistry & Molecular Biology
Markus Hoffmann et al.
Article
Immunology
Ling Ni et al.
Article
Immunology
Mingkai Tan et al.
Article
Multidisciplinary Sciences
Jian Shang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Multidisciplinary Sciences
Xiuyuan Ou et al.
NATURE COMMUNICATIONS
(2020)
Article
Immunology
Ruochen Zang et al.
SCIENCE IMMUNOLOGY
(2020)
Article
Public, Environmental & Occupational Health
Takahiko Koyama et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION
(2020)
Article
Biochemistry & Molecular Biology
Tyler N. Starr et al.
Article
Biochemistry & Molecular Biology
Bette Korber et al.
Article
Biochemistry & Molecular Biology
Leonid Yurkovetskiy et al.
Article
Biochemistry & Molecular Biology
Hangping Yao et al.
Article
Multidisciplinary Sciences
Hongjing Gu et al.
Article
Medicine, General & Internal
Barnaby E. Young et al.
Article
Multidisciplinary Sciences
Bethany Dearlove et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Cell Biology
Hongjie Xia et al.
Letter
Medicine, General & Internal
Bina Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Review
Oncology
Clea Melenotte et al.
Article
Microbiology
Jose L. Nieto-Torres et al.
Article
Virology
Everett Clinton Smith et al.
ANNUAL REVIEW OF VIROLOGY, VOL 1
(2014)
